GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

xeligekimab   Click here for help

GtoPdb Ligand ID: 13784

Synonyms: GR-1501 | GR1501
Approved drug Immunopharmacology Ligand
xeligekimab is an approved drug
Compound class: Antibody
Comment: Xeligekimab (GR1501) is a human IgG4 monoclonal antibody that targets IL-17A [2].
No information available.
Summary of Clinical Use Click here for help
Xeligekimab (GR-1501) is in clinical studies to determine safety and efficacy as a treatment for chronic inflammatory diseases, including plaque psoriasis, axial spondyloarthritis and lupus nephritis. It was first approved by the China NMPA in August 2024 [1]. Xeligekimab (Jinlixi®) is indicated to treat moderate to severe plaque psoriasis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05162937 to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2 Interventional Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT05881785 Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis Phase 3 Interventional Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT06802848 Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real) Observational Chongqing Genrix Biopharmaceutical Co., Ltd